Puretech Health LLC

Puretech Health LLC, doing business as Bio Pharmaceutical, is a for-profit corporate entity registered to receive federal government awards since May 27, 2009. The company specializes in biopharmaceutical research and development, focusing on innovative treatments for various medical conditions. Through federal grant awards, Puretech Health LLC contributes to advancing medical research and therapeutic interventions, particularly in the areas of neurological disorders and cancer treatment. The company's expertise appears to lie in developing and testing novel pharmaceutical compounds and conducting clinical trials to evaluate their efficacy and safety.

Puretech Health LLC has received federal grant awards from the Defense Health Agency, a component of the Department of Defense. Their recent grant-funded projects include a Phase 2 randomized, double-blind, placebo-controlled study of oral allopregnanolone (LYT-300) for treating premutation carriers with Fragile X-associated tremor/ataxia syndrome (FXTAS). This project, awarded in August 2023, aims to investigate a potential treatment for a specific genetic disorder. Another significant grant-funded project, awarded in September 2020, focuses on blood and tissue immunophenotyping in cancer patients treated with an anti-galectin-9 monoclonal antibody (LYT-200), both alone and in combination with anti-PD1 therapy. This research contributes to the field of cancer immunotherapy, exploring novel approaches to enhance the body's immune response against cancer cells. Both projects demonstrate Puretech Health LLC's involvement in cutting-edge medical research, with a focus on developing targeted therapies for complex medical conditions.